NCT01490112已完成不适用
Regulatory Post Marketing Surveillance Study of NovoRapid for New Drug Re-examination
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,239
- 试验地点
- 1
- 主要终点
- Change in weight
研究概览
简要总结
This study is conducted in Asia. The aim of this study is to observe the safety and efficacy of insulin aspart (NovoRapid®) administered via vial and three different devices.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with diabetes mellitus (type 1, type 2, or gestational) prescribed with insulin aspart (NovoRapid®)
排除标准
- 未提供
研究组 & 干预措施
IAsp
干预措施: insulin aspart (Drug)
结局指标
主要结局
Change in weight
次要结局
- Fasting blood glucose (FBG)
- HbA1c (glycosylated haemoglobin)
- Adverse events: Serious and non-serious
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1NCT01984372Novo Nordisk A/S6,163
已完成
不适用
A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in IndiaDiabetesDiabetes Mellitus, Type 2NCT01212133Novo Nordisk A/S1,386
已完成
不适用
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®DiabetesNCT02821052Novo Nordisk A/S1,355
已完成
不适用
NovoLet® Surveillance Study on Using Human Insulin System in IndonesiaDiabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2NCT01492153Novo Nordisk A/S1,981
已完成
不适用
Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)DiabetesDiabetes Mellitus, Type 2NCT02321878Novo Nordisk A/S1,092